Propanc Biopharma shares surge 10.68% premarket as PRP’s mesenchymal drift research advances, patent filed, and 2026 Phase 1b trial planned.

Propanc Biopharma (NASDAQ: PPCB) jumped 10.68% in premarket trading following announcements about its expansion into mesenchymal drift research, a patent application for PRP-based fibrotic disease treatment, and plans for a Phase 1b first-in-human trial in advanced solid tumors starting in 2026. The company highlighted PRP’s potential to reverse epithelial-to-mesenchymal transition (EMT) pathways linked to cancer and fibrosis, positioning it for broader chronic disease applications. The CEO noted these trials could lead to "blockbuster status," while joint researchers emphasized PRP’s scientific promise in addressing tumor progression and organ failure. The patent filing and clinical timeline underscore intellectual property and regulatory progress, aligning with the stock’s sharp premarket rise driven by optimism over PRP’s multi-indication potential and de-risked development strategy.